0001104659-14-082018.txt : 20141119
0001104659-14-082018.hdr.sgml : 20141119
20141119153442
ACCESSION NUMBER: 0001104659-14-082018
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20141117
FILED AS OF DATE: 20141119
DATE AS OF CHANGE: 20141119
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NPS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000890465
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 870439579
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 550 HILLS DRIVE
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
BUSINESS PHONE: (908) 450-5300
MAIL ADDRESS:
STREET 1: 550 HILLS DRIVE
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rogus Joseph J
CENTRAL INDEX KEY: 0001299691
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-23272
FILM NUMBER: 141234943
MAIL ADDRESS:
STREET 1: 550 HILLS DRIVE
STREET 2: 3RD FLOOR
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
4
1
a4.xml
4
X0306
4
2014-11-17
0
0000890465
NPS PHARMACEUTICALS INC
NPSP
0001299691
Rogus Joseph J
550 HILLS DRIVE
BEDMINSTER
NJ
07921
0
1
0
0
SVP, Gbl Technical Operations
Common Stock
2014-11-17
4
M
0
26782
3.34
A
46933
D
Common Stock
2014-11-17
4
S
0
26782
30.003
D
20151
D
Employee Stock Options (right to buy)
3.34
2014-11-17
4
M
0
26782
0
D
2020-02-19
Common Stock
26782
85343
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.18, inclusive. The reporting person undertakes to provide to NPS Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
On February 19, 2010, the reporting person was granted options to purchase shares of Common Stock under the Issuer's 2005 Omnibus Incentive Plan, which are subject to both performance conditions and time-based vesting. As of the date of this filing, the performance criteria and the time-based criteria for 112,125 of these options has been satisfied. These options vested and became exercisable based on the following vesting schedule: 25% on each of the first four anniversaries of the date of grant.
/s/ Joseph R. Rogus, by Jill Thompson as attorney in fact
2014-11-19